Research article
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
Arthritis Research & Therapy 2012, 14:R11 doi:10.1186/ar3685
See related editorial by Takeuchi and Kameda, http://arthritis-research.com/content/14/2/114
Accesses
- Last 30 days: 120 accesses
- Last 365 days: 1372 accesses
- All time: 2061 accesses

